Literature DB >> 33872324

Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone.

Jin Gao1, Hongquan Wan1, Xing Li1, Mira Rakic Martinez1, Laura Klenow1, Yamei Gao1, Zhiping Ye1, Robert Daniels1.   

Abstract

Virions are a common antigen source for many viral vaccines. One limitation to using virions is that the antigen abundance is determined by the content of each protein in the virus. This caveat especially applies to viral-based influenza vaccines where the low abundance of the neuraminidase (NA) surface antigen remains a bottleneck for improving the NA antibody response. Our systematic analysis using recent H1N1 vaccine antigens demonstrates that the NA to hemagglutinin (HA) ratio in virions can be improved by exchanging the viral backbone internal genes, especially the segment encoding the polymerase PB1 subunit. The purified inactivated virions with higher NA content show a more spherical morpn>hology, a shift in the balance between the HA receptor binding and NA receptor release functions, and induce a better NA inhibitory antibody response in mice. These results indicate that influenza viruses support a range of ratios for a given NA and HA pair which can be used to produce viral-based influenza vaccines with higher NA content that can elicit more balanced neutralizing antibody responses to NA and HA.

Entities:  

Year:  2021        PMID: 33872324     DOI: 10.1371/journal.ppat.1009171

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  6 in total

1.  Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.

Authors:  Jin Gao; Laura Klenow; Lisa Parsons; Tahir Malik; Je-Nie Phue; Zhizeng Gao; Stephen G Withers; John Cipollo; Robert Daniels; Hongquan Wan
Journal:  J Virol       Date:  2021-10-06       Impact factor: 5.103

2.  Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019-2020 circulating strains.

Authors:  Jin Gao; Xing Li; Laura Klenow; Tahir Malik; Hongquan Wan; Zhiping Ye; Robert Daniels
Journal:  NPJ Vaccines       Date:  2022-07-14       Impact factor: 9.399

Review 3.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

4.  Selection of an Optimal Recombinant Egyptian H9N2 Avian Influenza Vaccine Strain for Poultry with High Antigenicity and Safety.

Authors:  Se-Hee An; Seung-Eun Son; Jin-Ha Song; Seung-Min Hong; Chung-Young Lee; Nak-Hyung Lee; Young-Ju Jeong; Jun-Gu Choi; Youn-Jeong Lee; Hyun-Mi Kang; Kang-Seuk Choi; Hyuk-Joon Kwon
Journal:  Vaccines (Basel)       Date:  2022-01-21

5.  A Single Vaccination of Chimeric Bivalent Virus-Like Particle Vaccine Confers Protection Against H9N2 and H3N2 Avian Influenza in Commercial Broilers and Allows a Strategy of Differentiating Infected from Vaccinated Animals.

Authors:  Yi-Xue Sun; Zheng-Rong Li; Peng-Ju Zhang; Jin-Hong Han; Hai-Yang Di; Jia-Yi Qin; Yan-Long Cong
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

6.  Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.

Authors:  Miruna E Rosu; Adinda Kok; Theo M Bestebroer; Dennis de Meulder; Elwin P Verveer; Mark R Pronk; Lennard J M Dekker; Theo M Luider; Mathilde Richard; Judith M A van den Brand; Ron A M Fouchier; Sander Herfst
Journal:  J Virol       Date:  2022-02-02       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.